Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples